Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
RATIONALE: Bortezomib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractory T-cell lymphoma.
Epistemonikos ID: 6fba6a62cba0e0a5e51b1530521d80f81ae550b4
First added on: May 05, 2024